CA-GUIDEWIRE-SOFTWARE
11.5.2021 14:57:09 CEST | Business Wire | Press release
Guidewire Software, Inc. (NYSE: GWRE), the platform P&C insurers trust to engage, innovate, and grow efficiently, today announced the latest release of its market-leading cloud platform. Cortina will be unveiled at Connections Reimagined on May 11 and 12.* To register, visit connections.guidewire.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005561/en/
Cortina’s event-based, API-first Integration Framework accelerates the connection of Guidewire to other services enabling teams to automate more workflows, driving faster innovation. Closed-loop analytics delivers specific insights across the insurance lifecycle to help claims and underwriting professionals make better, faster decisions. And platform innovation across Application Services empowers developers to experiment and build faster to keep pace with evolving customer demands.
“The significant platform innovations in Cortina set a new bar for openness and reinvent how easy it is to integrate to Guidewire,” said Diego Devalle, chief product development officer, Guidewire. “Customers can quickly capitalize on market opportunities, handle claims in new ways, and offer new products in record time —like usage-based insurance with our recently announced UBI Solution —while developers are empowered to further innovate on top of Guidewire. We are, in essence, simplifying the business of insurance technology.”
Expanded Application Services makes integrations and other InsuranceSuite interactions easier to build and maintain.
- Guidewire Cloud Console—Enhanced tooling to enable IT self-service with provisioning and deployment, as well as database backups and restores. What used to take two people 20 days now takes one person 15 minutes to provision and deploy.
- Guidewire Claims Autopilot**—Cloud-based claims service that allows for an automation-first approach to claims handling, enabling insurers to leverage artificial intelligence, analytics, and digital technologies to deliver better customer experiences, while lowering operating expenses.
Insurers are empowered to make better-informed decisions with closed-loop analytics enabled by Data Studio.**
- Closed-loop analytics—A new holistic solution, Initial Segmentation for Auto/Motor Claims in ClaimCenter, improves claims processing efficiency.
- Data Studio**—A new data management tool to access, create, and publish business-ready data sets to enable insurers to leverage their data wherever it’s needed.
Integration Framework reduces the complexity of integrations across the P&C lifecycle.
- InsuranceSuite Cloud API expansion—Broader functional coverage enables apps to do more using the APIs. Further improving the Guidewire developer experience, the ClaimCenter API reference is now publicly available for developers to explore at developer.guidewire.com .
- Integration Gateway**—A new integration service that orchestrates calls to and from InsuranceSuite and third-party applications. Reduced integration complexity enables developers to drive more innovation.
- Application Events**—A new integration service enabling developers to easily publish event streams from InsuranceSuite that “push” data and events to external systems. This service automates more processes and enables insurers to create their own differentiating ecosystem of connected apps and services.
Since the launch of Aspen in May 2020, the company has been increasing the value of its platform with twice-yearly releases. Insurers are selecting Guidewire Cloud to upgrade from self-managed deployments, power greenfield implementations, and transition their core business. Thirty-three Guidewire InsuranceSuite customers have selected Guidewire Cloud and 12 are live.
Guidewire was positioned as a Leader in Gartner, Inc.’s most recent Magic Quadrant for Non-Life Insurance Platforms, Europe, 1 for the third consecutive year for InsuranceSuite. In addition, Guidewire was positioned as a Leader for the sixth consecutive time in Gartner, Inc.'s Magic Quadrant for P&C Core Platforms, North America 2 for InsuranceSuite and was named a Challenger for the fourth consecutive time in the same report for InsuranceNow.
To learn more about Cortina, visit our website and read the Cortina overview blog .
*Cortina release will be generally available on May 14, 2021.
**Indicates product feature is available for Early Access customers only.
1 Gartner, Magic Quadrant for Non-Life-Insurance Platforms , Europe , Sham Gill and Manav Sachdeva, September 21, 2020
2 Gartner, Magic Quadrant for P&C Core Platforms , North America , Venkatesh Padmanabhan, James Ingham, Sham Gill, October 20, 2020
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Guidewire
Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 400 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices . All products mentioned in this announcement are Guidewire products. Not all products are available in every geography or to self-managed customers. Any unreleased services or features referenced in this or other press releases or public statements are not currently available and may not be delivered on time or at all. Customers who purchase Guidewire applications should make their purchase decisions based upon features that are currently available.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the future availability of the Cortina release, the general availability of features, programs, services, and tools related to Cortina mentioned in this release such as, Guidewire Cloud Console, InsuranceSuite Cloud API expansion, closed-loop analytics, and InsuranceNow on Guidewire Cloud Platform, and early access features, programs, services and tools related to Cortina such as Guidewire Claims Autopilot, Data Studio, and a new event-based, API-first Integration Framework. Forward-looking statements include those preceded by, followed by or that include the words “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “plans,” “estimates,” “targets,” “projects,” “intends” or similar expressions. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the impact of the COVID-19 pandemic on our employees and our business and the businesses of our customers, system integrator partners, and vendors; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue; our ability to successfully manage any changes to our business model, including the transition of our products to cloud offerings and the costs related to cloud operations; intense competition in our market; weakened global economic conditions may adversely affect the P&C insurance industry including the rate of information technology spending; and other factors detailed in Guidewire’s most recent Form 10-Q filed with the Securities and Exchange Commission. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005561/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom